CLINICAL_TRIALS
research
· 2025-12-01
Clinical Trial Update: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) [Phase 1]
Summary
A Phase 1 study evaluating subcutaneous tarlatamab in patients with extensive-stage small cell lung cancer is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 1 | Status: RECRUITING